US2009286734A1PendingUtilityA1

Pharmaceutical Use of Alpha Antigen or Alpha Antigen Gene

61
Assignee: MARUHO KKPriority: Feb 20, 2001Filed: Mar 17, 2009Published: Nov 19, 2009
Est. expiryFeb 20, 2021(expired)· nominal 20-yr term from priority
A61P 37/08A61P 43/00A61P 27/16A61P 27/14A61P 27/00A61P 11/06A61K 2039/53A61P 17/00A61K 39/04
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The α antigen-encoding gene and the α antigen protein suppress the production of interleukin-4 etc., improve the Th2 type cytokine-dominant state, and furthermore inhibit various conditions of allergic diseases such as IgE production, histamine release and eosinophil infiltration, and therefore they are very effective for the prevention or treatment of atopic diseases such as atopic dermatitis, asthma, allergic rhinitis, and allergic conjunctivitis, and more broadly allergic diseases.

Claims

exact text as granted — not AI-modified
1 . A method for treating atopic dermatitis or asthma, comprising administering to a mammal in need of such treatment an effective amount of a polypeptide with at least 75% amino acid sequence identity to SEQ ID NO: 2. 
     
     
         2 . A method for treating atopic dermatitis or asthma, comprising administering to a mammal in need of such treatment an effective amount of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2. 
     
     
         3 . The method according to any one of  claims 1  and  2 , wherein said mammal is a human. 
     
     
         4 . The method according to any one of  claims 1  and  2 , wherein alveolar eosinophil infiltration in said mammal is decreased. 
     
     
         5 . The method according to  claim 1 , wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 2.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.